- Home
- WLDN vs TNGX Comparison
WLDN vs TNGX Comparison
Compare WLDN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLDN | TNGX |
|---|---|---|
| Founded | 1964 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | WLDN | TNGX |
|---|---|---|
| Price | $106.06 | $9.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $114.33 | $12.50 |
| AVG Volume (30 Days) | 203.7K | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.17 | N/A |
| EPS | ★ 2.79 | N/A |
| Revenue | ★ $651,926,000.00 | $66,501,000.00 |
| Revenue This Year | N/A | $53.01 |
| Revenue Next Year | $9.01 | N/A |
| P/E Ratio | $38.75 | ★ N/A |
| Revenue Growth | 12.90 | ★ 53.29 |
| 52 Week Low | $30.43 | $1.03 |
| 52 Week High | $121.00 | $11.20 |
Technical Indicators
Market Signals| Indicator | WLDN | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 52.50 |
| Support Level | $101.66 | $8.89 |
| Resistance Level | $105.88 | $10.22 |
| Average True Range (ATR) | 3.98 | 0.62 |
| MACD | 0.75 | -0.14 |
| Stochastic Oscillator | 76.45 | 21.34 |
Price Performance
Historical ComparisonAbout WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.